Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs

Basit Öğe Kaydı
dc.authoridAlkan Melikoglu, Meltem/0000-0001-7519-9470
dc.authoridcengiz, gizem/0000-0002-0021-7002
dc.authoridYurdakul, Ozan Volkan/0000-0003-4567-8133
dc.authoridmulkoglu, cevriye/0000-0001-9113-3885
dc.authoridOrhan, Kevser/0000-0001-8639-751X
dc.authoridAcer Kasman, Sevtap/0000-0002-4805-0555
dc.authoridSen, Nesrin/0000-0003-0966-0075
dc.contributor.authorKeskin, Yasar
dc.contributor.authorNas, Kemal
dc.contributor.authorKilic, Erkan
dc.contributor.authorSargin, Betul
dc.contributor.authorKasman, Sevtap Acer
dc.contributor.authorAlkan, Hakan
dc.contributor.authorSahin, Nilay
dc.date.accessioned2025-01-21T16:34:23Z
dc.date.available2025-01-21T16:34:23Z
dc.date.issued2021
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjectives: This study aims to compare the clinical characteristics, disease activity, and quality of life (QoL) of patients with psoriatic arthritis (PsA) who use biological and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in a nationwide cohort throughout Turkey. Patients and methods: A total of 961 patients (346 males, 615 females; mean age: 46.9+/-12.2 years; range, 18 to 81 years) with PsA according to the classification criteria for PsA were included in the study. The patients demographic and clinical characteristics, physical examination results, Disease Activity Score 28, Disease Activity Index for Psoriatic Arthritis and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Psoriasis Area and Severity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, Hospital Anxiety and Depression Scale, Health Assessment Questionnaire, Psoriatic Arthritis Quality of Life (PsAQoL), and Short Form-36 scores were all recorded. Results: Of the patients, 23% underwent biological DMARD (bDMARD) monotherapy, 42% underwent conventional synthetic DMARD (csDMARD) monotherapy, 10% underwent a csDMARD combination therapy, and 10% underwent a combination bDMARD and csDMARD treatment. The Visual Analog Scale (VAS pain), patient global assessment, physician global assessment, and BASDAI scores were found to be lower among patients using combination treatment of csDMARD and bDMARD, while the swollen joint count was found to be lower among patients using bDMARD. The PsAQoL score was found to be the lowest among patients not using any medication and the highest among those using bDMARD. Conclusion: In our study, patients with PsA were successfully treated with both csDMARD and bDMARD monotherapy. When the biological treatments used for PsA were compared with csDMARD, it was found that biological treatments had a positive effect on both disease activity and the QoL. Combinations of csDMARDs and bDMARDs were preferred in cases in which the disease activity was still high or increased. Because of the highest efficacy of the combined treatment, we highly suggest increasing the number of patients on combined treatment.
dc.identifier.doi10.46497/ArchRheumatol.2021.7874
dc.identifier.endpage9
dc.identifier.issn2148-5046
dc.identifier.issn1309-0283
dc.identifier.issue1
dc.identifier.pmid34046563
dc.identifier.scopus2-s2.0-85103053136
dc.identifier.scopusqualityQ3
dc.identifier.startpage1
dc.identifier.trdizinid465392
dc.identifier.urihttps://doi.org/10.46497/ArchRheumatol.2021.7874
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay465392
dc.identifier.urihttps://hdl.handle.net/20.500.12587/23958
dc.identifier.volume36
dc.identifier.wosWOS:000623526400001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish League Against Rheumatism
dc.relation.ispartofArchives of Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectDisease-modifying antirheumatic drug; functional status; psoriatic arthritis; quality of life
dc.titleClinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu